These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 28646789)
21. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA. Pariente A; Daveluy A; Laribière-Bénard A; Miremont-Salame G; Begaud B; Moore N Drug Saf; 2009; 32(5):441-7. PubMed ID: 19419238 [TBL] [Abstract][Full Text] [Related]
22. Risk of stress cardiomyopathy associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors: a real-world pharmacovigilance analysis. Tan B; Chen L; Yan S; Pan H; Zhang J; Wei H Sci Rep; 2024 Jul; 14(1):15167. PubMed ID: 38956425 [TBL] [Abstract][Full Text] [Related]
23. Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database. Tian X; Yao Y; He G; Jia Y; Wang K; Chen L Sci Rep; 2021 Jun; 11(1):12438. PubMed ID: 34127681 [TBL] [Abstract][Full Text] [Related]
24. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Mazhar F; Pozzi M; Gentili M; Scatigna M; Clementi E; Radice S; Carnovale C CNS Drugs; 2019 Jun; 33(6):581-592. PubMed ID: 30977109 [TBL] [Abstract][Full Text] [Related]
25. Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data. Li B; Zhang J; Huang A; Chen Y; Wei Q Int J Cardiol; 2024 Oct; 412():132305. PubMed ID: 38944350 [TBL] [Abstract][Full Text] [Related]
26. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database. Yin G; Song G; Xue S; Liu F Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547 [TBL] [Abstract][Full Text] [Related]
27. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421 [TBL] [Abstract][Full Text] [Related]
28. Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database. Seo DE; Kim S; Park BJ Clin Drug Investig; 2020 Sep; 40(9):873-881. PubMed ID: 32648200 [TBL] [Abstract][Full Text] [Related]
29. Signal detection of methylphenidate by comparing a spontaneous reporting database with a claims database. Kim J; Kim M; Ha JH; Jang J; Hwang M; Lee BK; Chung MW; Yoo TM; Kim MJ Regul Toxicol Pharmacol; 2011 Nov; 61(2):154-60. PubMed ID: 21510997 [TBL] [Abstract][Full Text] [Related]
30. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896 [TBL] [Abstract][Full Text] [Related]
31. Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system. Lee JE; Kim JH; Bae JH; Song I; Shin JY Sci Rep; 2022 Sep; 12(1):14869. PubMed ID: 36050484 [TBL] [Abstract][Full Text] [Related]
32. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Montastruc F; Sommet A; Bondon-Guitton E; Durrieu G; Bui E; Bagheri H; Lapeyre-Mestre M; Schmitt L; Montastruc JL Eur J Clin Pharmacol; 2012 May; 68(5):767-75. PubMed ID: 22116460 [TBL] [Abstract][Full Text] [Related]
33. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144 [TBL] [Abstract][Full Text] [Related]
34. Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016. Ha D; Choi SR; Kwon Y; Park HH; Shin JY Medicine (Baltimore); 2019 Aug; 98(33):e16785. PubMed ID: 31415382 [TBL] [Abstract][Full Text] [Related]
35. Analysis of data on capecitabine-related adverse drug reactions from the Korean adverse event reporting system database. Park JY Eur J Oncol Nurs; 2018 Jun; 34():55-60. PubMed ID: 29784139 [TBL] [Abstract][Full Text] [Related]
36. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database. Nagai J; Ishikawa Y PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908 [TBL] [Abstract][Full Text] [Related]
37. The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea. Yang BR; Lee JY; Kim MG J Dig Dis; 2022 Feb; 23(2):118-123. PubMed ID: 34965009 [TBL] [Abstract][Full Text] [Related]
38. Real-world data-based adverse drug reactions detection from the Korea Adverse Event Reporting System databases with electronic health records-based detection algorithm. Shin H; Cha J; Lee Y; Kim JY; Lee S Health Informatics J; 2021; 27(3):14604582211033014. PubMed ID: 34289723 [TBL] [Abstract][Full Text] [Related]
39. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database. Wang Y; Lin Y; Lin Q; Liang H; Cai W; Jiang D Sci Rep; 2023 Jul; 13(1):12257. PubMed ID: 37507539 [TBL] [Abstract][Full Text] [Related]
40. Model driven method for exploring individual and confounding effects in spontaneous adverse event reporting databases. Lv B; Li Y; Shi A; Pan J Expert Opin Drug Saf; 2024 Sep; 23(9):1173-1181. PubMed ID: 38073472 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]